Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 1 January 2026 - 3 January 2026

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

Eli Lilly stock (LLY) edges higher after hours today as drug-pricing reset and January catalysts loom

NEW YORK, Jan 2, 2026, 18:12 ET — After-hours Shares of Eli Lilly and Company rose about 0.5% in after-hours trading on Friday, last at $1,080.36. The stock swung between $1,052.96 and $1,080.49 during the regular session. The timing matters for drugmakers because early January is when many companies reset list prices — the sticker prices before rebates and discounts.…
3 January 2026
····
Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

Dyne Therapeutics (DYN) stock slides today as biotech wobbles — FDA clock back in focus

NEW YORK, Jan 2, 2026, 3:19 PM ET — Regular session Dyne Therapeutics shares fell about 6% on Friday, giving back earlier gains in a volatile first session of 2026 for some biotech names. The Nasdaq-listed stock was down 6.1% at $18.36 in afternoon trading, after touching $20.90 at the high and $18.13 at the low. The move matters because…
2 January 2026
···
Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

Corcept Therapeutics (CORT) stock rebounds today after FDA setback — here’s what investors are watching next

NEW YORK, January 2, 2026, 2:30 PM ET — Regular session Corcept Therapeutics Incorporated shares were up 5.7% at $36.77 on Friday afternoon, after a sharp selloff earlier in the week tied to a U.S. regulatory setback for its experimental drug relacorilant. The bounce matters because the FDA’s decision hit what investors had seen as a key growth driver beyond…
2 January 2026
····
AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

AbbVie stock edges up today as Linzess partner Ironwood cuts list price, lifts 2026 outlook

NEW YORK, Jan 2, 2026, 14:08 ET — Regular session AbbVie shares ticked higher on Friday after Ironwood Pharmaceuticals, its partner on constipation drug Linzess, raised its 2026 outlook and said it lowered the medicine’s list price at the start of the year. The update matters because Linzess is co-developed and co-commercialized with AbbVie in the U.S., and changes in…
2 January 2026
···
Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

Pfizer stock rises today as 2026 drug price hikes grab headlines again — what PFE investors are watching

NEW YORK, January 2, 2026, 13:56 ET — Regular session Pfizer Inc shares rose 0.8% to $25.09 on Friday, as investors digested renewed attention on U.S. drug pricing and early-year list-price changes. The timing matters. January is when drugmakers typically reset U.S. prices, and the moves can quickly become a political and regulatory flashpoint — especially as the Trump administration…
2 January 2026
····
Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

Pfizer stock slips before the bell as 2026 drug price hikes put PFE back in focus

NEW YORK, Jan 2, 2026, 09:18 ET — Premarket Pfizer Inc shares fell 0.4% to $24.90 in premarket trading on Friday after a Reuters report said the drugmaker plans to raise U.S. list prices on around 80 medicines in 2026. Reuters The pricing moves matter now because January is when drugmakers typically reset U.S. list prices, a closely watched “sticker…
2 January 2026
····
Novo Nordisk stock slips premarket as China court backs key semaglutide patent

Novo Nordisk stock slips premarket as China court backs key semaglutide patent

NEW YORK, January 2, 2026, 05:42 ET — Premarket Novo Nordisk A/S shares edged lower in premarket trading on Friday after the Danish drugmaker said China’s Supreme People’s Court upheld a key patent covering semaglutide, the active ingredient in its blockbuster obesity and diabetes drugs. U.S.-listed American depositary receipts (ADRs) — certificates that represent foreign shares — were down about…
2 January 2026
··
AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

AXSM stock jumps after FDA sets April 30 decision date for Axsome’s AXS-05 in Alzheimer’s agitation

NEW YORK, January 1, 2026, 21:06 ET — Market closed Axsome Therapeutics shares jumped 22.9% in the Dec. 31 session, ending at $182.64 after the company disclosed two U.S. FDA updates that put near-term regulatory milestones back in focus. The stock traded between $148.79 and $184.40 on the day, with about 3.1 million shares changing hands. The move matters because…
2 January 2026
···
Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

Pfizer stock today: PFE slips as report flags 2026 U.S. drug price hikes

NEW YORK, January 1, 2026, 20:51 ET — Market closed Pfizer Inc (PFE) shares last traded at $24.90, down 0.4% from the previous close, with U.S. markets closed on Thursday for the New Year’s Day holiday. Reuters reported Pfizer is leading a new round of U.S. list-price increases for 2026, planning hikes on around 80 drugs and vaccines — including…
2 January 2026
····
Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

Eli Lilly stock forecast 2026: Analysts see modest upside as pricing pressure bites

NEW YORK, January 1, 2026, 17:27 ET Drugmakers plan to raise U.S. list prices on at least 350 branded medicines in 2026, according to data from healthcare research firm 3 Axis Advisors. The median increase is about 4%, and the figures do not reflect rebates or other discounts. The same dataset showed drugmakers also plan to cut list prices on…
1 January 2026
···
Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

Corcept Therapeutics stock tanks on FDA relacorilant setback — what happens next for CORT

NEW YORK, January 1, 2026, 3:46 PM ET — Market closed. Corcept Therapeutics (CORT.O) shares ended the last U.S. session down 50.4% at $34.80 after the Food and Drug Administration declined to approve the company’s drug relacorilant for a rare hormonal-disorder-related blood-pressure condition. StockAnalysis U.S. stock markets are closed on Thursday for New Year’s Day, leaving investors to digest the…
1 January 2026
····
1 … 14 15 16 17 18 … 46

Stock Market Today

  • Tradeweb Markets Stock Shows Signs of Overvaluation Amid Price Decline
    January 22, 2026, 4:14 PM EST. Tradeweb Markets (TW) shares have fallen 2.3% year to date but still boast strong long-term returns, up 42.1% over three years and 74.9% over five. However, valuation analysis indicates the stock may be overvalued. The Excess Returns model values TW at around $67.27, well below its recent price near $103.75, suggesting a 54.2% overvaluation. This model assesses profits above investor-required returns, emphasizing sustainable returns on equity over near-term earnings fluctuations. Despite recent price softness, Tradeweb's role in electronic trading platforms keeps it under market watch. Investors should weigh these valuation concerns carefully against the company's position in the ongoing shift toward digital trading markets.
Go toTop